retatrutide fda approval status november 2025 The has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide: The Unapproved Drug America

Glycemic control changes typically occur within days to weeks after stopping GLP-1 therapy

It may also be possible that the weight loss changes how the body builds and breaks down bone, Dr

When stimulant misuse occurs alongside other substances such as alcohol or illicit drugs, the health risks may increase

Other critical B vitamins B12 gets most of the attention, but other B vitamins also deplete during GLP-1 therapy

And establishing consistent eating patterns, rather than relying on appetite suppression alone to regulate intake, creates a behavioral foundation that persists even when the pharmacological support is reduced or removed